What is Merck's Lipfendra and why is its FDA approval significant?

Merck’s Lipfendra is the first oral PCSK9 inhibitor approved by the FDA for adults with high cholesterol. Its approval marks a major shift from injectable biologics to oral therapy, potentially improving patient adherence and payer coverage while giving Merck a chance to capture market share in cholesterol treatment.